Phytanic acid accumulation most commonly occurs in the setting of Refsum disease, a rare neurologic disorder characterized by numbness and weakness in the arms and legs. Most frequently, Refsum disease is due to a genetic mutation in the gene for phytanoyl-CoA α-hydroxylase (PHYH), which is involved in the metabolism of phytanic acid. Less frequently, it can be caused by a mutation of the gene for peroxin 7 receptor protein (PEX7).
Both mutations are typically inherited in an autosomal recessive pattern, meaning an individual must inherit a copy of the mutation from each parent to develop the condition.
PHYH and PEX7 are responsible for the breakdown, or metabolism, of phytanic acid to pristanic acid. The metabolism of phytanic acid occurs by a unique process known as alpha-oxidation, which differs from the more common beta-oxidation of fatty acids. Alpha-oxidation occurs in the peroxisome of the cell, which is a membrane-bound organelle responsible for the breakdown of many molecules, including certain fatty acids and amino acids. The genetic mutation that occurs with Refsum disease alters the peroxisome’s ability to break down phytanic acid, eventually causing the body to accumulate large stores of phytanic acid in the blood and tissues, including the nervous system, retina of the eye, skin, and heart.
Ultimately, excess phytanic acid prevents proper growth and function of the myelin sheath, which is the fatty layer that surrounds nerves and protects them from damage.